| Eligibility |
Inclusion Criteria:
1. For patients with colon cancer (Group 1): Adenocarcinoma of the colon (radiologic T4
and/or N2) OR rectal adenocarcinoma with positive lymph nodes and/or
threatened/positive circumferential resection margin (CRM).
Radiological staging is based on the degree of tumor infiltration beyond the serosa:
- rT1-2 tumors - no tumor extension beyond the serosa.
- rT3 tumors - tumor extension <5 mm beyond the serosa.
- rT4 tumors - tumor extension =5 mm beyond the serosa.
Lymph nodes are considered positive if they are more than 10 mm in short axis diameter
or demonstrate an irregular contour:
- rN0 - absence of nodal involvement.
- rN1 - involvement of 1-3 nodes.
- rN2 - involvement of = 4 nodes.
2. For patients with rectal cancer (Group 1): Patients with rectal adenocarcinoma must
have completed neoadjuvant chemoradiation therapy (or planned to receive neoadjuvant
chemoradiation at point of recruitment).
3. Colon or Rectal Cancer patients referred for preoperative chemotherapy (Group 2).
Note: Patients may be included at any point during the preoperative chemotherapy phase
and have pembrolizumab administered concurrently with the remaining cycles of
preoperative chemotherapy.
4. Male/female participants who are at least 21 years of age on the day of signing
informed consent with histologically confirmed diagnosis of colorectal adenocarcinoma.
5. Female participants: A female participant is eligible to participate if she is not
pregnant, not breastfeeding, and at least one of the following conditions applies: a)
Not a woman of childbearing potential (WOCBP) OR b) A WOCBP who agrees to follow the
contraceptive guidance during the treatment period and for at least 120 days after the
last dose of study treatment.
6. The participant (or legally acceptable representative if applicable) provides written
informed consent for the trial.
7. Tumor evaluated to have sufficient tissue for translational studies
8. Have provided sufficient archival tumor tissue sample.
9. Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.
Evaluation of ECOG is to be performed within 7 days prior to the date of
allocation/randomization.
10. Have adequate organ function as defined in the following table. Specimens must be
collected within 14 days prior to the start of study treatment.
Adequate Organ Function Laboratory:
- Absolute neutrophil count (ANC): =1500/µL.
- Platelets: =100 000/µL.
- Hemoglobin: =9.0 g/dL or =5.6 mmol/L.
- Creatinine OR Measured or calculated creatinine clearance: =1.5 × Upper Limit of
Normal (ULN) OR =30 mL/min for participant with creatinine levels >1.5 ×
institutional ULN
- Total bilirubin: =1.5 ×ULN OR direct bilirubin =ULN for participants with total
bilirubin levels >1.5 × ULN.
- Alanine Aminotransferase and Aspartate Aminotransferase: =2.5 × ULN.
- Coagulation - International normalized ratio (INR) OR prothrombin time (PT) OR
Activated partial thromboplastin time (aPTT): =1.5 × ULN.
11. Are not on current anti-HCV treatment for subjects with chronic infection by HCV. For
subjects who have had anti-HCV therapy, the last dose of anti-HCV medication should be
at least 4 weeks before first dose of pembrolizumab.
Note: Screening for chronic HCV infection will be done if subject's HCV status is not
already known.
12. Have HBV viral load under 100 IU/mL with or without treatment, for subjects with
chronic hepatitis B infection.
- HBV viral load must be less than 100 IU/mL on at least 4 weeks of anti-viral
therapy prior to first dose of pembrolizumab. Subjects on active HBV therapy with
viral loads under 100 IU/mL should stay on the same therapy throughout study
treatment. Subjects who are anti-HBc (+), negative for HBs Ag, negative for
anti-HBs, and have an HBV viral load under 100 IU/mL do not require HBV
anti-viral prophylaxis
Exclusion Criteria:
1. A WOCBP who has a positive urine pregnancy test within 72 hours prior to allocation of
subject number. If the urine test is positive or cannot be confirmed as negative, a
serum pregnancy test will be required.
2. Has any sign of distant metastases or need for emergency surgery.
3. Has past history of bowel perforation and abdominal fistula, unless medically treated
(e.g. by stoma) or deemed to still be suitable for pre-operative systemic therapy; a
recent history of bowel resection (within past 12 months) and/or patients with
radiological evidence of active bowel obstruction.
4. Has intercurrent illness, including but not limited to infections and unstable angina
pectoris.
5. Is on anticoagulation therapy (warfarin, low molecular weight heparin, rivaroxaban).
6. Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with
an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g.,
CTLA-4, OX-40, and CD137).
7. Has received prior systemic anti-cancer therapy including investigational agents
within 1 year prior to allocation, except capecitabine as neoadjuvant therapy for
patients with rectal cancer.
Note: Participants must have recovered from all AEs due to previous therapies to
=Grade 1 or baseline. Participants with =Grade 2 neuropathy may be eligible.
Note: If participant received major surgery, they must have recovered adequately from
the toxicity and/or complications from the intervention prior to starting study
treatment
8. Has received prior radiotherapy within 1 year of start of study treatment or planned
radiotherapy prior to surgery, except radiotherapy received as neoadjuvant therapy for
patients with rectal cancer.
9. Has received a live vaccine within 30 days prior to the first dose of study drug.
Examples of live vaccines include, but are not limited to, the following: measles,
mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus
Calmette-Guérin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection
are generally killed virus vaccines and are allowed; however, intranasal influenza
vaccines (e.g., FluMist®) are live attenuated vaccines and are not allowed.
10. Is currently participating in or has participated in a study of an investigational
agent or has used an investigational device for cancer within 1 year prior to the
first dose of study treatment.
Note: Participants who have entered the follow-up phase of an investigational study
may participate as long as it has been 4 weeks after the last dose of the previous
investigational agent.
11. Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy
(in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of
immunosuppressive therapy within 7 days prior to the first dose of study drug.
12. Has a known additional malignancy that is progressing or has required active treatment
within the past 3 years.
13. Has severe hypersensitivity (=Grade 3) to pembrolizumab and/or any of its excipients.
14. Has active autoimmune disease that has required systemic treatment in the past 2 years
(i.e. with use of disease modifying agents, corticosteroids or immunosuppressive
drugs). Replacement therapy (e.g. thyroxine, insulin, or physiologic corticosteroid
replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a
form of systemic treatment.
15. Has a history of (non-infectious) pneumonitis that required steroids or has current
pneumonitis.
16. Has an active infection requiring systemic therapy.
17. Has Human Immunodeficiency Virus (HIV).
18. Has a known history of active TB (Bacillus Tuberculosis).
19. Has a history or current evidence of any condition, therapy, or laboratory abnormality
that might confound the results of the study, interfere with the subject's
participation for the full duration of the study, or is not in the best interest of
the subject to participate, in the opinion of the treating investigator.
20. Has known psychiatric or substance abuse disorders that would interfere with
cooperation with the requirements of the trial.
21. Is pregnant, breastfeeding, or expecting to conceive or father children within the
projected duration of the study, starting with the screening visit through 120 days
after the last dose of trial treatment.
22. Has dual active HBV infection [HBsAg (+) and/or detectable HBV DNA] and HCV infection
[anti-HCV Ab (+) and detectable HCV RNA] at study entry.
|
